ATAiko Takami

Aiko Takami

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aiko Takami has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Right Heart Catheterisation with Dobutamine Stress Test for Evaluation of Right Ventricular Outflow Tract Obstruction 30 Years After Surgical Repair of Tetralogy of Fallot

    by Kengo Yasuda, Tomomi Watanabe, Aiko Takami, Toshihiko Akasaka, Yasushi Yoshikawa, Motonobu Nishimura, Kazuhiro Yamamoto

    Right ventricular outflow tract obstruction was suspected in a 32-year-old man with repaired tetralogy of Fallot and borderline indications for surgical. Right heart catheterisation with a dobutamine stress test was useful in assessing the dynamics and severity of right ventricular outflow tract obstruction and in determining the treatment strategy.

  • Open Access

    Impact of BMI and Type of Ablation Procedure on Atrial Fibrillation Recurrence in Japanese Patients

    by Aiko Takami, Junichiro Miake, Masaru Kato, Kazuyoshi Ogura, Akihiro Okamura, Takuya Tomomori, Daiki Tsujimoto, Syunsuke Kawatani, Masahiko Kato, Kazuhiro Yamamoto

    Background: AF recurs more frequently after catheter ablation in individuals with a high BMI than it does in those with a normal BMI. However, the association between AF recurrence and BMI may be influenced by race. The authors investigated the relationship between BMI and AF recurrence after catheter ablation in Japanese patients. Methods: They enrolled 726 consecutive patients with paroxysmal or persistent AF (241 patients classified as overweight/obese [BMI ≥25 kg/m2] and 485 classified as non-overweight/obese [BMI <25 kg/m2]) who underwent cryoablation or radiofrequency ablation. The relationship between BMI and AF recurrence was assessed. Results: AF recurred in 183 patients (25.2%; 105 with paroxysmal AF and 78 with persistent AF). Median BMI differed significantly between patients with and without AF recurrence (23.9 kg/m2 [interquartile range: 21.6–26.9] versus 23.2 kg/m2 [interquartile range: 21.3–25.4]; p=0.011). Fisher’s exact test showed that the AF recurrence rate increased significantly with BMI in the radiofrequency ablation group (non-overweight/obese: 23.9% versus overweight/obese: 44.6%; p<0.001) but not in the cryoablation group (non-overweight/obese: 19.3% versus overweight/obese: 18.0%; p=0.883). Patients classified as overweight/obese had a significantly larger left atrial dimension, and left atrial dimension increased synergistically with persistent AF and increasing BMI. Conclusion: The AF recurrence rate in Japanese patients who underwent radiofrequency ablation, but not in those who underwent cryoablation, increased with BMI (especially BMI ≥25 kg/m2). Cryoablation may be superior to radiofrequency ablation in Japanese patients classified as overweight/obese.


  • Open Access

    Simple Score to Predict Treatment Response to Low-Dose Tolvaptan in Patients with Heart Failure

    by Aiko Takami, Yoshiharu Kinugasa, Hiroko Kamitani, Kensuke Nakamura, Masayuki Hirai, Kiyotaka Yanagihara, Koichi Matsubara, Masahiko Kato, Kazuhiro Yamamoto

    The recommended starting dose of Tolvaptan for heart failure (HF) is 7.5 mg/day in Japan; the recommended dose is 3.75 mg/day for older patients to avoid excessive diuresis and hypernatremia. However, low-dose Tolvaptan may delay the release of congestion in some patients. We aimed to develop a score to predict treatment responders to 3.75 mg tolvaptan.We retrospectively analyzed 106 patients with HF who initially received 3.75 mg/day of Tolvaptan in the derivation cohort (April 2013-December 2017) and 63 patients receiving 3.75 mg/day of Tolvaptan in the validation cohort (January 2018-April 2021). Treatment responders to 3.75 mg tolvaptan did not require dose escalation of Tolvaptan for congestion relief. In multivariate analysis, blood urea nitrogen (BUN) < 39 mg/dL and hematocrit > 35% were selected as variables to predict treatment responders. These were assigned 1 point each, and patients were stratified into groups with 2 points (n = 32), 1 point (n = 39), and 0 points (n = 35). The frequency of treatment responders was 82.9% in the 2-point group, 61.5% in the 1-point group, and 34.4% in the 0-point group (P < 0.05). The predictive ability of the score was acceptable with an area under the receiving operator characteristic curve (AUC) 0.726 (P < 0.05); its performance was maintained in the validation cohort (AUC 0.733, P < 0.05).A simple score using BUN and hematocrit could identify treatment responders to 3.75 mg tolvaptan, which may help determine the appropriate starting dose of Tolvaptan, balancing efficiency with safety for older patients with HF.

  • Open Access

    Successful Chemotherapy With Early Leadless Pacemaker Implantation for a Giant Malignant Lymphoma Complicated by Unstable Atrioventricular Block and Superior Vena Cava Syndrome

    by Fumiyasu Hirano, Akihiro Okamura, Masaru Kato, Kazuyoshi Ogura, Takuya Tomomori, Aiko Takami, Shunsuke Kawatani, Kazuhiro Yamamoto

    Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.


  • Open Access

    Reply to Letter Regarding Article, "Simple Score to Predict Treatment Response to Low-Dose Tolvaptan in Patients with Heart Failure"

    by Aiko Takami, Yoshiharu Kinugasa, Kazuhiro Yamamoto

    Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.

  • Open Access

    Novel inhibitory effects of dotinurad, a selective urate reabsorption inhibitor, on urate crystal-induced activation of NLRP3 inflammasomes in macrophages

    by Fikri Taufiq, Peili Li, Masanari Kuwabara, Yasutaka Kurata, Toshihiro Hamada, Aiko Takami, Junichiro Miake, Motokazu Tsuneto, Yasuaki Shirayoshi, Kimiyoshi Ichida, et al.

    Background:When macrophages are primed by lipopolysaccharides, mono sodium urate (MSU) crystals activate NLRP3 inflammasomes and promote IL-1β and IL-18 production after phagocytosis of MSU. It was previously reported that anti-IL-1β antibodies suppress symptoms of gout and the occurrence of cardiovascular disease. Thus, inhibition of NLRP3 inflammasomes, which produce IL-1β and IL-18, may be a novel therapeutic strategy against these diseases. Purpose:To reveal the effects of dotinurad, a selective urate reabsorption inhibitor, and other uric acid lowering agents on MSU crystal-induced activation of NLRP3 inflammasomes in macrophages. Methods:Activity of NLRP3 inflammasomes in J774 mouse macrophages was evaluated by quantifying secreted caspase-1 and IL-1β using a western blot and ELISA in both the absence and presence of dotinurad or other uric acid lowering agents. Results:MSU increased protein levels of caspase-1 and IL-1β. This effect was inhibited by a clinical concentration of dotinurad. Neither febuxostat nor allopurinol influenced the levels of caspase-1 and IL-1β, whereas benzbromarone decreased their levels. The inhibitory effects of dotinurad and other uric acid lowering agents on secretions of IL-1β from the macrophages were confirmed by ELISA. Conclusion:Dotinurad, a selective urate reabsorption inhibitor, suppresses MSU-induced activation of NLRP3 inflammasomes in macrophages.